Skip Navigation



IJE Advance Access published online on September 28, 2009
International Journal of Epidemiology, doi:10.1093/ije/dyp297
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Klein, M. B
Right arrow Articles by Walmsley, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, M. B
Right arrow Articles by Walmsley, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2009; all rights reserved.

Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study

Marina B Klein1,*, Sahar Saeed1, Hong Yang1, Jeff Cohen2, Brian Conway3, Curtis Cooper4, Pierre Côté5, Joseph Cox6, John Gill7, David Haase8, Shariq Haider9, Julio Montaner10, Neora Pick11, Anita Rachlis12, Danielle Rouleau13, Roger Sandre14, Mark Tyndall11,15 and Sharon Walmsley16

1Department of Medicine, Divisions of Infectious Diseases/Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre, Montréal, Québec, Canada.
2Windsor Regional Hospital Metroplitan Campus, Windsor, Ontario, Canada.
3Department of Pharmacology and Therapeutics, University of British Columbia, Faculty of Medicine, Vancouver, British Columbia, Canada.
4The Ottawa Hospital-General Campus, Ottawa, Ontario, Canada.
5Clinique Médicale du Quartier Latin, Montreal, Quebec, Canada.
6Departments of Epidemiology, Biostatistics & Occupational Health, Medicine and Family Medicine, Immunodeficiency Treatment Centre, Montreal General Hospital, McGill University Health Centre and Infectious Diseases, Public Health Department, Health and Social Services Agency of Montreal, Montréal, Québec, Canada.
7Southern Alberta HIV Clinic, Calgary, Alberta, Canada.
8Capital District Health Authority, Halifax, Nova Scotia, Canada.
9McMaster University, Hamilton, Ontario, Canada.
10BC Centre for Excellence in HIV/AIDS and the University of British Columbia, Vancouver, British Columbia, Canada.
11Oak Tree Clinic, Children's and Women's Health Centre of British Columbia, University of British Columbia, Vancouver, British Columbia, Canada.
12Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
13Centre Hospitalier de l'Université de Montréal, Université de Montréal, Département de Microbiologie et Immumunologie, Montreal, Quebec, Canada.
14HAVEN group, Hôpital Régional de Sudbury Regional Hospital (HRSRH), Sudbury, Ontario, Canada.
15Native Health Clinic, Vancouver, British Columbia, Canada.
16University Health Network, University of Toronto, Ontario, Canada.

* Corresponding author. Montreal Chest Institute, 3650 Saint Urbain Street, Montreal, Quebec H2X 2P4, Canada. E-mail: marina.klein@mcgill.ca

Accepted 3 August 2009

The first 150 words of the full text of this article appear below.


   What is the Canadian HIV–Hepatitis C Co-infection Cohort and how did the study come about?
 
Hepatitis C virus (HCV) has emerged as one of the most vexing health problems facing HIV-infected persons. Due largely to injection drug use (IDU), >30% of HIV-infected patients are co-infected with HCV in developed countries1,2 with 10 million co-infected worldwide.3 In 1999, 11 194 Canadians were estimated to be co-infected4 and this number has likely increased substantially since. HCV infection has also increasingly been reported in HIV-positive men having sex with men (MSM) who have not used injection drugs.5 Since the advent of highly active antiretroviral therapy (HAART) there have been dramatic reductions in morbidity and mortality from virtually all causes of illness among HIV-infected persons.6,7 One of the glaring exceptions to this trend is death from end-stage liver disease (ESLD) with rates increasing 4- to 8-fold in the post-HAART era.8–11 This excess mortality may be due, in part, to improved overall survival associated with HAART, allowing competing morbidities and . . . [Full Text of this Article]


   How is the CCC organized?
 

   What does the CCC cover and who are included in the cohort?
 

   What are the primary objectives?
 

   What has been measured?
 

   What are the recruitment and attrition rates?
 

   How are the data collected and managed?
 

   Knowledge translation and dissemination
 
Twice-yearly meetings

   What has been found? Key findings and publications
 

   What are the main strengths and weaknesses?
 

   How can I collaborate? Where can I find out more?
 
Process for adding new sites
Process for outside collaborators

   Conclusions
 

   Funding
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?